Market Closed -
Nasdaq
16:00:00 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
3.8
USD
|
-1.81%
|
|
-20.67%
|
+1.60%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,479
|
7,933
|
5,587
|
980.4
|
368.8
|
432.5
|
-
|
-
|
Enterprise Value (EV)
1 |
1,258
|
7,450
|
4,971
|
544.2
|
53.6
|
230.8
|
308.4
|
331.5
|
P/E ratio
|
-13.6
x
|
-43.3
x
|
-26.1
x
|
-3.47
x
|
-2.28
x
|
-2.04
x
|
-2.24
x
|
-2.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
139
x
|
252
x
|
100
x
|
10.2
x
|
5.8
x
|
91.4
x
|
89.2
x
|
69.3
x
|
EV / Revenue
|
118
x
|
237
x
|
89
x
|
5.65
x
|
0.84
x
|
48.8
x
|
63.6
x
|
53.1
x
|
EV / EBITDA
|
-
|
-
|
-23.5
x
|
-1.85
x
|
-0.31
x
|
-1.08
x
|
-1.42
x
|
-1.39
x
|
EV / FCF
|
-13.9
x
|
-169
x
|
-23.3
x
|
-1.92
x
|
-0.39
x
|
-1.66
x
|
-1.9
x
|
-2.21
x
|
FCF Yield
|
-7.2%
|
-0.59%
|
-4.3%
|
-52.1%
|
-258%
|
-60.4%
|
-52.7%
|
-45.4%
|
Price to Book
|
-
|
-
|
8.25
x
|
2.03
x
|
0.98
x
|
1.62
x
|
1.52
x
|
2.39
x
|
Nbr of stocks (in thousands)
|
75,593
|
87,244
|
95,494
|
97,170
|
98,602
|
113,817
|
-
|
-
|
Reference price
2 |
19.57
|
90.93
|
58.51
|
10.09
|
3.740
|
3.800
|
3.800
|
3.800
|
Announcement Date
|
20-03-02
|
21-02-24
|
22-02-28
|
23-02-28
|
24-02-26
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
10.68
|
31.43
|
55.85
|
96.3
|
63.53
|
4.729
|
4.85
|
6.24
|
EBITDA
1 |
-
|
-
|
-211.1
|
-294.6
|
-172.2
|
-213.4
|
-216.9
|
-239.3
|
EBIT
1 |
-100.7
|
-128.1
|
-217
|
-308.4
|
-190.5
|
-212
|
-220.7
|
-253.9
|
Operating Margin
|
-943.14%
|
-407.47%
|
-388.56%
|
-320.23%
|
-299.86%
|
-4,482.76%
|
-4,549.58%
|
-4,069.66%
|
Earnings before Tax (EBT)
1 |
-98.15
|
-173.4
|
-212.2
|
-281.7
|
-160.9
|
-195.1
|
-211.4
|
-251.8
|
Net income
1 |
-98.15
|
-173.4
|
-212.2
|
-281.7
|
-160.9
|
-195.1
|
-211.4
|
-251.9
|
Net margin
|
-919%
|
-551.59%
|
-379.89%
|
-292.55%
|
-253.3%
|
-4,126.05%
|
-4,358.55%
|
-4,036.21%
|
EPS
2 |
-1.440
|
-2.100
|
-2.240
|
-2.910
|
-1.640
|
-1.863
|
-1.699
|
-1.812
|
Free Cash Flow
1 |
-90.57
|
-44.16
|
-213.6
|
-283.8
|
-138.4
|
-139.3
|
-162.7
|
-150.3
|
FCF margin
|
-848.03%
|
-140.49%
|
-382.43%
|
-294.68%
|
-217.86%
|
-2,946.1%
|
-3,353.95%
|
-2,409.19%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-02
|
21-02-24
|
22-02-28
|
23-02-28
|
24-02-26
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
14.22
|
17.07
|
18.41
|
18.55
|
14.98
|
44.36
|
58.98
|
0.933
|
1.944
|
1.676
|
1.26
|
1.273
|
1.28
|
1.121
|
0.675
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-43.19
|
-49
|
-49.52
|
-50.05
|
-
|
-
|
EBIT
1 |
-54.62
|
-69.38
|
-74.47
|
-83.11
|
-86.39
|
-64.42
|
-28.59
|
-62.56
|
-51.28
|
-48.08
|
-50.65
|
-52.5
|
-54.44
|
-54.45
|
-52.42
|
Operating Margin
|
-383.99%
|
-406.48%
|
-404.4%
|
-448.05%
|
-576.67%
|
-145.23%
|
-48.48%
|
-6,705.79%
|
-2,637.81%
|
-2,868.44%
|
-4,019.52%
|
-4,122.76%
|
-4,252.84%
|
-4,855.34%
|
-7,766.12%
|
Earnings before Tax (EBT)
1 |
-43.31
|
-68.62
|
-65.69
|
-76.1
|
-83.56
|
-56.36
|
-18.88
|
-52.76
|
-45.17
|
-44.12
|
-46.81
|
-47.89
|
-49.18
|
-51.36
|
-51.81
|
Net income
1 |
-43.31
|
-68.62
|
-65.69
|
-76.1
|
-83.56
|
-56.36
|
-18.88
|
-52.76
|
-45.17
|
-44.12
|
-46.8
|
-47.89
|
-49.17
|
-51.32
|
-51.71
|
Net margin
|
-304.45%
|
-402.02%
|
-356.74%
|
-410.29%
|
-557.79%
|
-127.07%
|
-32.01%
|
-5,654.34%
|
-2,323.56%
|
-2,632.58%
|
-3,714.13%
|
-3,761.04%
|
-3,841.19%
|
-4,576.65%
|
-7,661.11%
|
EPS
2 |
-0.4500
|
-0.7200
|
-0.6800
|
-0.7800
|
-0.8600
|
-0.5800
|
-0.1900
|
-0.5400
|
-0.4600
|
-0.4500
|
-0.4717
|
-0.4658
|
-0.4692
|
-0.4667
|
-0.4450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-04
|
22-02-28
|
22-05-04
|
22-08-03
|
22-11-03
|
23-02-28
|
23-05-03
|
23-08-08
|
23-11-08
|
24-02-26
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
221
|
483
|
616
|
436
|
315
|
202
|
124
|
101
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-90.6
|
-44.2
|
-214
|
-284
|
-138
|
-139
|
-163
|
-150
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-39.9%
|
-48.5%
|
-37.8%
|
-66%
|
-90.4%
|
-70.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
7.090
|
4.970
|
3.810
|
2.340
|
2.500
|
1.590
|
Cash Flow per Share
2 |
-
|
-
|
-1.720
|
-2.560
|
-1.340
|
-1.900
|
-1.500
|
-
|
Capex
1 |
7.4
|
4.93
|
50.7
|
35.6
|
6.15
|
4
|
8.67
|
12
|
Capex / Sales
|
69.24%
|
15.69%
|
90.79%
|
36.93%
|
9.68%
|
84.58%
|
178.69%
|
192.31%
|
Announcement Date
|
20-03-02
|
21-02-24
|
22-02-28
|
23-02-28
|
24-02-26
|
-
|
-
|
-
|
Average target price
7.8
USD Spread / Average Target +105.26% Consensus |
1st Jan change
|
Capi.
|
---|
| +1.60% | 433M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|